Avanzanite Bioscience, a commercial-stage European specialty pharmaceutical company focused on rare diseases, announced a €32 million growth investment from MVM Partners, a global life-science private equity firm. The funding follows a record Q3 2025, with revenue rising sharply year-on-year and consistently quarter-on-quarter. The capital will accelerate the expansion of Avanzanite’s pan-European infrastructure, support upcoming rare-disease product launches, and enable new strategic alliances and asset acquisitions.
Avanzanite was created to address Europe’s rare-disease access gap by operating under a single pan-European structure that integrates commercial expertise, scientific capabilities, and cross-regional functions in market access, pricing, and reimbursement. This model enables biotech and pharma innovators to deliver rare-disease therapies across all 32 European markets, an area where conventional commercial approaches often fall short.
“We are truly honoured to partner with MVM, a top-tier investor in life sciences. Their investment is far more than capital – it demonstrates conviction in our mission and belief in the ‘Champions League’ team that powers Avanzanite,” said Adam Plich, Founder and CEO of Avanzanite. “With MVM’s support we will scale faster, expand with new partnerships and assets, and advance towards our 2032 vision of a pan-European platform with more than ten rare disease alliances – setting a new European standard for orphan medicine commercialisation and patient access. While this milestone reflects how far we’ve come, it is just the beginning of our journey”, concluded Plich.
In three years and through three strategic alliances, Avanzanite has established itself as a preferred partner for companies seeking to unlock the European potential of orphan therapies. The current portfolio includes medicines in nephrology, ophthalmology, and haematology, supported by exclusive licensing or distribution rights across the European Economic Area, the UK, and Switzerland.
MVM is investing up to €32 million from its €500 million sixth fund and has reserved additional capital to support future expansion. MVM becomes Avanzanite’s first institutional investor and joins the Board of Directors.
Dr. Jack Tanaka, Partner at MVM, commented, “For years MVM has watched promising rare disease medicines struggle to find a path to patients – Avanzanite breaks this pattern. In a short space of time, Avanzanite has successfully launched multiple rare disease products. Their experienced leadership team and pan-European footprint make them the stand-out partner. We are excited to support Avanzanite in bringing more transformative therapies to patients across Europe”.